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Chapter 5
surgical versus transcatheter pulmonary 
vein isolation as first invasive treatment in 
patients with atrial fibrillation: A matched 
group comparison
G.E. De Maat, I.C. Van Gelder, M. Rienstra, A.F.B.E. Quast, E.S. Tan, A.C.P. Wiesfeld, 





Aims. Pulmonary vein isolation (PVI) can be considered for treatment of symptomatic 
atrial fibrillation (AF). Nowadays, in addition to transcatheter ablation, thoracoscopic sur-
gical PVI is available. The aim of present study is to compare clinical outcome of surgical 
with transcatheter PVI as first invasive treatment strategy of AF.
Methods. From June 2009 to November 2011, 33 patients underwent minimally invasive 
surgical PVI, and were matched (1:2 fashion) retrospectively according to age, sex, and AF 
type, with 66 patients who underwent transcatheter PVI. Success was defined as freedom 
from atrial arrhythmias on 24h Holter monitoring without use of anti-arrhythmic drugs 
(AADs) at one year.
Results. Mean age was 52±10 years, 82% were male. Paroxysmal AF was present in 76 
patients (77%), persistent AF in 23 (23%). None underwent prior ablations, and failed on 
1.2±0.6 AADs. At 12 months, complete freedom from atrial arrhythmias without AADs in 
the surgical PVI group was 88% compared to 41% in the transcatheter PVI group (p<0.001). 
Freedom from atrial arrhythmias with AADs was 91% versus 62%, in the surgical versus 
transcatheter PVI group, respectively (p=0.002). Complications occurred in 7 (21%) surgi-
cal PVI, and 3 (5%) transcatheter PVI patients (p=0.015).
Conclusions. In present matched study comparing a surgical with transcatheter PVI treat-
ment strategy in symptomatic AF patients failed on AADs, but without prior ablations, a 
surgical PVI strategy was more effective to prevent recurrence of atrial arrhythmias, than 
a transcatheter PVI treatment strategy. However, complications were more frequent with 
surgical PVI.
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Atrial fibrillation (AF) has a major impact on health care in the Western population and 
is associated with poor prognosis(1,2). AF is associated with impaired quality of life, and 
two-third of the AF-patients are symptomatic(3). According to the European Society of 
Cardiology (ESC) guidelines, pharmacological rhythm-control therapy is recommended 
for symptomatic AF patients. However, antiarrhythmic drugs (AADs) are only moderately 
effective maintaining sinus rhythm and have known adverse effects(4,5). Non-pharma-
cological therapies have been introduced in the last decade to improve rhythm-control 
therapy(6). Transcatheter pulmonary vein isolation (PVI) is a widespread and well-
established technique to prevent recurrence of AF(1,2). Transcatheter PVI is reported to 
be effective in 61-89% of patients, with a complication rate of 6%(7). In approximately 
one-third of the patients multiple transcatheter ablations are necessary(7). Surgical treat-
ment for AF was first described by Cox et al(8). Long-term results of the Maze-III operation 
are excellent, with freedom from symptomatic AF up to 90% at 10-year(9,10). However, 
this invasive procedure proved technically demanding which limited the popularity and 
applicability. Therefore, minimally invasive surgical PVI, using bipolar radiofrequency (RF) 
and other energy sources has been developed and is applicable through video assisted 
thoracoscopic (VATS) approach,(11-13) 65-82% freedom from AF without AADs has been 
reported in small series(14-17). Surgical PVI has a class IIb recommendation in current ESC 
AF guidelines for patients with a failed transcatheter PVI(18). In the recently published 
“Atrial Fibrillation: Ablation or Surgical Treatment (FAST)” study, surgical PVI was superior 
to transcatheter PVI with regard to freedom from AF in patients who failed on at least 
one AAD and the majority had undergone a prior transcatheter PVI, although a higher 
complication rate of surgical PVI was reported(19). The aim of the present study was to 
compare the efficacy and safety of surgical and transcatheter PVI as first invasive treat-
ment strategy for AF.
METHoDs
We compared a surgical PVI and a transcatheter PVI treatment strategy in patients with 
paroxysmal or short-lasting persistent AF, who failed on at least one AAD, but without 
prior ablation. Potential PVI candidates were seen at the outpatient department by a 
cardiothoracic surgeon and an electrophysiologist, and were good candidates for either 
procedure. After informing the patient, and after reading the addition patient informa-
tion of both procedures, the final decision was led to the discretion of the patient. The 
surgical PVI group consisted of 33 consecutive patients, operated between June 2009 
and November 2011. The thoracic surgeon (MM) who performed the surgical PVIs, had 
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performed >50 surgical PVI procedures. Patients treated with surgical PVI were matched 
retrospectively 1:2 according to age, sex, and duration of AF, with patients who underwent 
transcatheter PVI in the same calendar period. In total, 66 patients treated with transcath-
eter PVI, were selected from the University Medical Center Groningen PVI database. Both 
electrophysiologists (ACPW, EST) who performed the transvenous PVIs were experienced 
and had performed > 500 PVI procedures. Exclusion criteria for surgical PVI were left 
atrial size >55mm (parasternal view), prior transcatheter PVI, prior heart or lung surgery, 
significant coronary disease or previous myocardial infarction, left ventricle hypertrophy 
>12mm, previous hospitalization for heart failure, left ventricular dysfunction (ejection 
fraction <50%), moderate or severe mitral- or aortic valve disease, or lung disease (prior 
tuberculosis or chronic obstructive pulmonary disease Gold class III-IV). All patients were 
eligible for the transcatheter PVI according to ESC AF guidelines(18).
Patients were admitted to the hospital 2 days prior to surgical or transcatheter PVI. Oral 
anticoagulation was discontinued two days before the procedure and replaced by full-dose 
low-molecular-weight heparin. At admission, a trans-oesophageal echocardiography was 
performed to exclude atrial thrombi and computed tomography (CT) scan was performed 
to document the anatomy of the pulmonary veins and left atrium.
The surgical PVI consisted of a minimal invasive off-pump bilateral video assisted thoracic 
surgery (VATS), which was performed under general anaesthesia and selective lung ven-
tilation. First, the right pulmonary veins were accessed from the right side, through two 
5-mm ports and one 10-mm port in a diamond-shape configuration, according to patient’s 
body size and shape. After right lung deflation, the pericardium was opened and blunt 
dissection was used to surround the right pulmonary veins. A bipolar clamp (AtriCure, 
Inc, Cincinnati, Ohio USA) using RF, was used to achieve 3-5 linear ablation lesions(12). 
To confirm PVI, in all patients direct pacing (120bpm, 18mV output, 200Hz) was applied 
on the pulmonary veins (exit blocks). Then, from the left side, the left pulmonary veins 
were targeted in the same manner. Whenever active ganglionic plexi were found these 
were additionally ablated using the monopolar Isolator Pen (Atricure Inc, Cincinnati, Ohio 
USA)(20,21). Ganglionic plexi were tested for inducibility by high rate pacing and ablated. 
Successful ablation was confirmed by the absence of a vagal response after ablation. No 
additional linear ablation lines were applied on the atria and the left atrial appendage was 
not amputated.
The transcatheter, wide circumferential PVI was performed as described by Pappone 
under local anesthesia using the Seldinger technique through the right femoral vein and 
subsequently through the atrial septum by puncture(22). A bidirectional steerable sheath 
(Agilis® St. Jude Medical Inc., St. Paul, MN, USA) was employed. One decapolar catheter 
(Cordis-Webster, Miami, FL, USA) with 5-mm electrodes and 2-mm inter-electrode spacing 
was placed in the coronary sinus. A bolus of unfractionated heparin was administered 
after the first transseptal puncture and subsequently, an additional bolus of heparin after 
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two hours. The left atrium and the pulmonary veins were mapped and reconstructed using 
CARTO FAM 3D electro-anatomic maps (Biosense-Webster, Diamond Bar, CA, USA). Then 
the CARTO® left atrium map was aligned to the CT scan reconstruction of the left atrium. 
Point-by-point ablation lines were created, circumferating each pulmonary vein using RF 
pulses in unipolar mode via the distal catheter electrode (EZ-steer Biosense Webster, CA, 
USA)(23). Radiofrequency energy was delivered at a temperature setting of 60°C, with a 
power limit of 40 W during 40 seconds, except for the posterior atrium where a maximum 
of 30 W was delivered during 30 seconds. In case of an impedance rise, cough, burning 
pain or severe bradycardia, RF delivery was stopped. After deployment of the contiguous 
focal lesions, measurement of the effective electrical disconnection was performed only 
by pacing within the pulmonary veins (exit block), no fixed diameter steerable decapolar 
circumferential catheter (Lasso, Biosense Webster, CA, USA) was employed. If patients 
were in AF before measurement, a cardioversion was performed. During the first proce-
dure, no additional linear ablation lines or CAFE ablations were performed. If AF recurred 
or flutter occurred, 3 months after the first transcatheter PVI, the completing of the lines 
around the pulmonary veins was checked, and if necessary, lines were completed. Ad-
ditional lines ablation was performed at the discretion of the treating electrophysiologist, 
or in case of a typical atrial flutter a cavotricuspid isthmus (CTI) ablation was performed.
After the PVI procedure patients were treated with full-dose low-molecular-weight hepa-
rin. In the surgical group oral anticoagulation was restarted one month post procedure 
(to prevent bleeding), and low-molecular-weight-heparin was stopped when INR>2.0 was 
reached. In the transcatheter group oral anticoagulation was immediately post-procedure 
restarted, and low-molecular-weight-heparin was stopped when INR>2.0 was reached. 
Oral anticoagulation treatment was determined based on the CHADS2VA2Sc score for 
stroke(1,2). AADs were continued during the first three months(24).
Patients treated with surgical PVI were seen at 1 week, 1, 3, 6, and 12 months post-PVI. In 
the transcatheter group, patients were first seen at 3 months post ablation, and at 6 and 
12 months. To assess the occurrence of (a)symptomatic atrial arrhythmias, at 6 months 
96-hour Holter monitoring and at 12 months 24-hour Holter monitoring was performed. At 
each visit a routine 12-lead ECG was performed, and when atrial arrhythmia was detected, 
a 12-lead rhythm strip (>30 seconds) was produced. The indication for a re-PVI procedure 
was based on the presence of symptomatic atrial arrhythmias, patient preference, and led 
to the discretion of the treating physician. Echocardiography was performed at all visits 
except at 6 months, when a cardiac CT scan was performed to document possible poten-
tial pulmonary vein stenosis. In addition to standard echocardiographic measurements, 
we measured atrial dimensions and total atrial conduction time. Left atrial (LA) volume 
was calculated and corrected for body surface area (BSA) with the following formula: 
((0.523*LA parasternal* LA length * LA width) / BSA) / 1000. Total atrial conduction time 
(TACT) is the time between initiation of the electrocardiographic P-wave and the peak 
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velocity of the left atrial free wall measured with tissue velocity imaging, and is a measure 
for atrial conduction(24). Pre-ablation and at 12-months quality of life (QoL) was assessed 
using the validated Dutch SF-36 questionnaire(25).
Primary efficacy endpoint was freedom of atrial arrhythmias after one or more PVI 
procedures, i.e. no evidence of AF, atrial flutter, or other atrial arrhythmias with a dura-
tion >30 seconds, without use of AADs at twelve months, or at end of follow-up. This 
in accordance with the definitions as described in the 2012 expert consensus statement 
on AF ablation(26). Secondary efficacy endpoints were freedom from atrial arrhythmias 
with the use of AADs, quality of life, and atrial diameters, total atrial conduction time and 
volume. Recurrences of AF were censored within the first three months (blanking period) 
to prevent unjustified classification of failure(27).
Primary safety end point was the occurrence of procedural and post-procedural complica-
tions. Complications were defined as an event that resulted in death or permanent injury, 
in temporarily injury that required intervention or specific treatment, or (prolonged) 
hospitalization >48 hours (eg. stroke, transient ischemic attack, major bleeding requiring 
surgery or blood transfusion or >2.0 points hemoglobin decrease, cardiac tamponade and/
or perforation, significant/symptomatic PV stenosis >70%, pericarditis and/or pericardial 
effusion, acute coronary syndrome, myocardial infarction, fluid retention, nervus phreni-
cus lesion, pneumothorax, wound infections, empyema, pneumonia, peri-procedural 
conversion to thoracotomy, and other not pre-defined events).
Baseline descriptive statistics are presented as mean ± standard deviation or median 
(range) for continuous variables, depending on the normality of the data, and counts with 
percentages for categorical variables. Differences between both groups (surgical versus 
transcatheter PVI), at baseline, during follow-up and end of study were evaluated by 
the Student t test or the Mann-Whitney U test, depending on normality of the data, for 
continuous data. Fischer’s exact test was used for comparison of categorical variables. 
Kaplan-Meier analysis was used to assess freedom from atrial arrhythmias. Data was 
censored for patients with recurrence of atrial arrhythmias, completed follow-up duration 
or reached the last date of follow-up, whichever came first. Statistical significance was 
considered at the level of p<0.05. The statistical software package IBM SPSS Statistics 20 
was used for the analyses.
REsulTs
Of the 99 patients included in this study, 33 consecutive patients were treated with surgi-
cal PVI, the other 66 patients were treated with transcatheter PVI (Table 1). Mean age was 
52±10 years; 81 (82%) were male. Atrial fibrillation was paroxysmal in 76 (77%) patients 
and persistent in 23 (23%). Median time from first AF to ablation was 50 months (range 
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Age (years) 51±10 53±9 0.53
Male 27 (82%) 54 (82%) 1.00
Type of AF 0.21
 Paroxysmal 28 (85%) 48 (73%)
 Persistent 5 (15%) 18 (27%)
Total duration AF (months) 41 [5-203] 58 [8-344] 0.16
Hypertension 10 (30%) 28 (44%) 0.28
Diabetes mellitus - 4 (6%) 0.30
Coronary artery disease - 3 (5%) 0.55
Chronic obstructive pulmonary disease 1 (3%) 4 (6%) 0.66
Complaints AF
 Palpitations 22 (67%) 53 (80%) 0.15
 Dyspneu 9 (27%) 13 (20%) 0.45
 Fatigue 6 (18%) 15 (23%) 0.80
 Chest pain 4 (12%) 4 (6%) 0.44
Previous class I AAD







Body Mass Index (kg/m²) 28±3 28±4 0.93
Body Surface Area (m²) 2.2±0.2 2.2±0.2 0.53
Systolic blood pressure (mmHg) 126±20 128±18 0.66
Diastolic blood pressure (mmHg) 74±9 80±9 0.008
Echocardiographic measurements
 LA volume (ml) 29.5±9.1 28.3±8.6 0.56
 Parasternal LA diameter (mm) 41.7±5.4 40.8±5.4 0.46
 LVEDD (mm) 51.0±4.4 51.2±6.1 0.88
 LVESD (mm) 33.2±5.8 34.0±6.8 0.57
Medication at baseline
 Oral anticoagulation 16 (48%) 52 (78%) 0.003
 Beta blocker 18 (55%) 33 (50%) 0.83
 Verapamil 7 (21%) 10 (15%) 0.57
 Digoxin 1 (3%) 3 (5%) 0.10
 ACE-I 4 (12%) 20 (30%) 0.051
 ARB 5 (15%) 14 (21%) 0.59
Antiarrhythmic drugs
 Flecainide 17 (52%) 24 (36%) 0.20
 Sotalol 7 (21%) 13 (20%) 1.00
 Amiodarone 3 (9%) 13 (20%) 0.25
Total atrial conduction time (ms) 127±22 128±23 0.87
AADs= anti arrhythmic drugs; ACE-I= Angiotensin Converting Enzyme inhibitor; AF=atrial fibrillation; ARB= 
angiotensin receptor blocker; LA=left atrium; LVEDD= Left ventricular end diastolic diameter; LVESD= Left 
ventricular end systolic diameter; PVI=pulmonary vein isolation.
Chapter 5
56
5-344) and patients had failed on 1.2±0.6 AADs. At baseline there were no significant dif-
ferences between both groups, except for diastolic blood pressure, which was lower in the 
surgical group (74 mmHg versus 80 mmHg, p=0.003) and oral anticoagulation use, which 
was higher in the transcatheter group (48% versus 79%, p=0.002).
Mean intervention time of the surgical PVI was 155±33 minutes compared to 199±54 
minutes of the transcatheter PVI (p<0.001). In all surgical PVI procedures, acute success 
was reached and confirmed by acute exit blocks, whereas after first transcatheter PVI, in 
14 patients conduction block was doubtful and in 2 patients conduction block was not 
achieved. Further, in 2 transcatheter PVI patients it was not possible to isolate the right 
pulmonary veins. During the surgical PVI, ganglionated plexi were found and additionally 
ablated in 25 (76%) patients, which was not performed in the transcatheter PVI group. 
Following surgical PVI, hospitalization was 8.4±4 days, compared to 2.4±2 days in the 
transcatheter group (p<0.001).
Mean follow-up was 12.6±2 months. Two patients in the surgical group, and 2 in the 
transcatheter group did not complete the 12-month follow-up. Last follow-up in those 
patients was the 6-month visit. Three (9%) surgical PVI patients underwent an additional 
transcatheter ablation, and 1 (3%) patient underwent 2 additional transcatheter abla-
tions. In 3 patients the combination of surgical and transcatheter PVI led to freedom from 
atrial arrhythmias. In the transcatheter group 25 (38%) patients underwent a second PVI 
procedure, and 1 (1%) patient underwent a third procedure. At 12 months, 7 (11%) trans-
catheter PVI patients were awaiting a second ablation and 7 (11%) were awaiting a third 
ablation. In the surgical group, no patients were awaiting additional ablative procedures.
Freedom from atrial arrhythmia without AADs occurred in 27 patients (87%) in the surgical 
and in 27 (42%) in the transcatheter group (p<0.001). Freedom from atrial arrhythmia 
with AADs occurred in 28 patients (90%) in the surgical and in 4 (63%) in the transcatheter 
group (p=0.007). Kaplan Meier curves are depicted in figure 1A. In figure 1B, we show the 
Kaplan Meier curves, excluding the patients awaiting an additional ablation procedure (n= 
14 in the transcatheter PVI group).
In the surgical PVI-group, 7 (21%) patients developed a major complication in the post-
operative phase, compared to 3 (5%) in the transcatheter group (p=0.015). In the surgical 
group 2 patients required intervention by VATS for evacuation of a tamponade, one during 
hospital admission, the other patient was re-admitted 5 days after surgery. Another patient 
with pericardial effusion was re-admitted, but did not require treatment and recovered 
completely. One patient had a hemoglobin decrease of 2.3 mg/dl, although only 300ml 
periprocedural blood loss was recorded, and blood transfusion was not required. One 
patient developed a peri-operative cerebrovascular accident with partial recovery. A tran-
sient unilateral paralysis of the diaphragm was also recorded, and a prolonged hospitaliza-
tion for fluid retention requiring diuretics. In the transcatheter group, one patient suffered 
from a peri-procedural tamponade, which required immediate drainage, another patient 
57






had a bleeding from the groin, requiring surgical intervention. Furthermore, one patient 
had a prolonged hospitalization due to a peri-procedural allergic reaction on local anes-
thetic drug. All transcatheter patients recovered completely. During 12-months follow-up, 
no other cardiovascular events, i.e. stroke, major bleeding, myocardial infarction, heart 
failure hospitalization or death occurred in both treatment strategies.
Quality of life (QoL) questionnaires were obtained from 19 (58%) patients in surgical PVI 
group and 30 (45%) in transcatheter PVI group. At baseline, there were no significant 
differences between both groups. After 12 months follow-up, 5 domains of the SF-36 




In figure 1A all 99 patients were included, in figure 1B those awaiting an additional ablation were excluded 
(n=14, all in the transcatheter group).
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questionnaire were statistically significant different between both groups, in favour of the 
surgical PVI group (figure 2). At 12 months, surgical PVI group showed significant increase 
in QoL in 6 out of 8 domain whereas transcatheter PVI group showed no significant in-
crease in QoL, except for the domain of social functioning.
Baseline and follow-up echocardiographic data was available in 33 (100%) surgical PVI 
group and 57 (86%) in transcatheter PVI group (Table 2). No change in LA diameter and 
volume was observed between baseline and end of follow-up. Since sinus rhythm (and 
adequate P-wave detection) is mandatory for total atrial activation time (TACT)-measure-
ment, data is only available in a subset of patients with sinus rhythm at baseline and at 
follow-up (Both baseline and follow-up TACT measurements were available in 18 (55%) 
patients of the surgical group and 19 (29%) of the transcatheter group). No significant 
change in total atrial conduction time was observed in both groups between baseline and 
12 months, TACT was significantly longer (139ms) in the transcatheter group compared to 
the surgical group (116ms) at 12 months (p=0.001).






LA volume (ml) 26.9±7.7 27.0±8.7 0.98
Parasternal LA diameter (mm) 42.3±5.5 40.2±5.7 0.13
Total atrial conduction time (ms) 116±16 139±27 0.001
LA =left atrial; PVI=pulmonary veins isolation.
























    Quality of Life at 12 months follow-up 
SORT CASES  BY rand_STRAT. 
*  
*  
*  *  
*  
*p<0.05, difference between groups. PVI=transcatheter pulmonary vein isolation; sPVI=surgical pulmonary 
vein isolation.
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In present matched study comparing a surgical with transcatheter PVI treatment strategy 
in symptomatic patients failed on antiarrhythmics, but without prior PVI ablations, a surgi-
cal PVI strategy is more effective than a transcatheter PVI strategy. However, the incidence 
of complications was higher with surgical PVI.
Freedom from AF after surgical PVI is reported in 65-92% of paroxysmal AF patients, and 
67-80% in persistent AF patients(28). A systematic review of 752 patients after surgical PVI 
(with and without additional ablation lines) showed a single procedure success rate of 69% 
without AADs in patients with paroxysmal or persistent AF(29). In our study, surgical PVI 
showed 88% success at 12 months follow-up.
In the transcatheter group freedom of atrial arrhythmias, without AADs, was 42%, and 
when excluding those waiting for an additional ablation, freedom of atrial arrhythmias 
without AADs was 52%. The efficacy of transcatheter PVI has been investigated extensively 
and compared with pharmacological therapy in multiple randomized clinical trials. For 
example, Wilber et al. randomized a comparable population of 167 patients with parox-
ysmal AF to ablation or pharmacologic therapy(30). At 12 months follow-up, the catheter 
ablation resulted in 66% freedom of AF. These results are better than achieved in our 
population. This may be due to the fact that in our transcatheter population 27% of the 
patients had persistent AF, at one year 7 (11%) were awaiting a second PVI and 7 (11%) 
were awaiting a third procedure, and we measured the acute effectiveness of electrical 
disconnection only by pacing within the pulmonary veins (exit block), and no steerable 
decapolar circumferential catheter was employed, which may have negatively influenced 
our efficacy results.
Recently, in the randomized FAST trial, a direct comparison of surgical PVI with transcath-
eter PVI was performed. The authors found 66% freedom from AF after surgical PVI, and 
37% after transcatheter PVI (both without AADs)(19). However, in that study patients had 
more progression of AF. The majority of patients had failed on a prior transcatheter PVI, 
the others had enlarged left atria. This in contrast to the surgical PVI patients in our study, 
where none of the patients had a prior ablation, enlarged atria (LA >55mm) and AF was 
present for a shorter period of time and persistent AF was less frequent (15% compared 
to 26% in the FAST-study). There are various possibilities to explain the better outcome of 
surgical compared to transcatheter PVI. Firstly, surgical PVI with bipolar RF entails continu-
ous ablation lines, compared to the point-by-point ablation line created with transcatheter 
RF ablation. Secondly, with transcatheter PVI the achievement of transmural lesions and 
permanent electrical conduction block is difficult. This because of variations in left atrial 
wall thickness, fibrosis, and anatomical location of the pulmonary veins. Furthermore, 
after acute conduction block is achieved by transcatheter PVI, electrical reconduction has 
been described(31). Data regarding electrical reconduction with surgical PVI are unavail-
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able yet. Thirdly, with surgical PVI we performed the additional treatment of active gangli-
onic plexi(21). The benefit of active ganglionic plexi ablation remains controversial since 
the potential beneficial effect has never been investigated in a randomized clinical trial 
and the long-term results (possible pro-arrhythmic effect) remain to be studied(32). But 
it may potentially have increased the outcome of the surgical PVI procedure(20). Lastly, 
the higher success rate of surgical ablation may have also been influenced by the fact that 
surgical patients seemed to have less comorbidities, although this was not statistically 
significant.
Furthermore, although we had only limited QoL data and our studied was not blinded, 
quality of life was significantly improved and better in patients treated with surgical PVI, 
than in those with transcatheter PVI. Furthermore, echocardiographically measured left 
atrial size was not different between the surgical and transcatheter PVI groups. The total 
atrial conduction time (TACT), measured by tissue Doppler imaging in a subset of patients 
who were in sinus rhythm at the time of echocardiography, was comparable at baseline 
but significantly shorter in the surgical PVI group at 12 months. Although the limited 
number of TACT measurements precludes any definite conclusions, reduced TACT without 
change of left atrial size may indicate less conduction delay, i.e. reduction of the atrial 
remodeling process in the surgical PVI group.
The complication rate was higher with surgical PVI. The complication rate of surgical PVI in 
the present study was comparable to the 23% observed in the randomized FAST trial. Also, 
the complication rate in the transcatheter PVI group in our study was comparable to prior 
reports(33). This difference is not completely unexpected since surgery is a more invasive 
procedure than transcatheter PVI. Comparison of complications between both procedures 
is difficult because of the differences in approach and invasiveness. Of the surgical PVI 
patients with a post-operative complication, 6 of 7 recovered completely, and in 2 of 7 
patients (transient unilateral paralysis of the diaphragm and periprocedural hemoglobin 
decrease of 2.3 points) no intervention was required. Hence, comparing surgical to trans-
catheter PVI, higher efficacy combined with a higher risk of complications of the surgical 
PVI has to be weighed against the less effective but also less invasive procedure of the 
transcatheter PVI. Large randomized clinical trials are warranted to study the outcome, 
both freedom for atrial arrhythmias, but even more important freedom of AF-associated 
cardiovascular morbidity and mortality of both PVI strategies. While awaiting the results 
of randomized PVI trials, our results may assist physicians to select the most appropriate 
patient-tailored therapy.
The extensive and consistent follow-up represents important strengths. However, our 
study has limitations that merit consideration. Present study was a retrospective matched 
group comparison, patients were not randomly assigned to a treatment strategy, and any 
possible referral bias cannot be excluded. Furthermore, only a relatively small number 
of patients were included. Lastly, we may have overlooked asymptomatic atrial arrhyth-
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mias, although we performed multiple 24-96 hr Holter monitoring in addition to ECG and 
rhythm-strips.
ConClusIons
A minimal invasive surgical PVI treatment strategy was more effective in preventing recur-
rence of atrial arrhythmias during 12 months follow-up, compared to a transcatheter PVI 
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